HK1150850A1 - Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf - Google Patents

Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf

Info

Publication number
HK1150850A1
HK1150850A1 HK11104796.5A HK11104796A HK1150850A1 HK 1150850 A1 HK1150850 A1 HK 1150850A1 HK 11104796 A HK11104796 A HK 11104796A HK 1150850 A1 HK1150850 A1 HK 1150850A1
Authority
HK
Hong Kong
Prior art keywords
tnf
treatment
disease
superfamily receptors
splice switching
Prior art date
Application number
HK11104796.5A
Other languages
English (en)
Chinese (zh)
Inventor
Henrik Rum
Peter L Sazani
Original Assignee
桑塔里斯製藥公司
厄克爾生物技術股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/799,117 external-priority patent/US7785834B2/en
Priority claimed from PCT/US2007/010556 external-priority patent/WO2008051306A1/en
Application filed by 桑塔里斯製藥公司, 厄克爾生物技術股份有限公司 filed Critical 桑塔里斯製藥公司
Publication of HK1150850A1 publication Critical patent/HK1150850A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
HK11104796.5A 2007-05-01 2011-05-16 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf HK1150850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/799,117 US7785834B2 (en) 2005-11-10 2007-05-01 Soluble TNF receptors and their use in treatment of disease
PCT/US2007/010556 WO2008051306A1 (en) 2006-10-20 2007-05-01 Soluble tnf receptors and their use in treatment of disease
PCT/EP2007/061211 WO2008131807A2 (en) 2007-05-01 2007-10-19 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease

Publications (1)

Publication Number Publication Date
HK1150850A1 true HK1150850A1 (en) 2012-01-13

Family

ID=39929868

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11104796.5A HK1150850A1 (en) 2007-05-01 2011-05-16 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf
HK15105622.8A HK1205184A1 (en) 2007-05-01 2015-06-15 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15105622.8A HK1205184A1 (en) 2007-05-01 2015-06-15 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf

Country Status (10)

Country Link
US (1) US20120142759A1 (ja)
EP (1) EP2147103B1 (ja)
JP (2) JP2010524476A (ja)
KR (5) KR101738655B1 (ja)
CN (2) CN101889086B (ja)
AU (6) AU2007352163A1 (ja)
CA (4) CA3165250A1 (ja)
HK (2) HK1150850A1 (ja)
MX (2) MX2009011856A (ja)
WO (1) WO2008131807A2 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
ES2647452T3 (es) 2006-08-08 2017-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Estructura y uso de oligonucleótidos 5' fosfato
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
US9518259B2 (en) 2010-06-15 2016-12-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP2906255B1 (en) * 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3394258B1 (en) 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
CN109328236B (zh) 2016-06-17 2022-10-25 豪夫迈·罗氏有限公司 体外肾毒性筛选测定法
CN109312403B (zh) 2016-06-17 2023-06-27 豪夫迈·罗氏有限公司 体外肾毒性筛选测定法
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
EP3339408B1 (en) * 2016-12-22 2020-01-29 The Procter & Gamble Company Fabric softener composition having improved dispensing properties
SG11202001103QA (en) * 2017-08-11 2020-03-30 Agency Science Tech & Res Method for screening splicing variants or events
TW201934750A (zh) 2017-12-22 2019-09-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之間隙子(gapmer)寡核苷酸
MX2020006430A (es) 2017-12-22 2020-09-17 Roche Innovation Ct Copenhagen As Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
WO2019122277A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
EP3914232A1 (en) 2019-01-25 2021-12-01 F. Hoffmann-La Roche AG Lipid vesicle for oral drug delivery
KR102470669B1 (ko) * 2022-06-03 2022-11-25 충남대학교 산학협력단 스플라이싱-스위치 올리고뉴클레오티드를 유효성분으로 포함하는 폴리프로모 1 유전자의 스플라이싱 조절용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410324B1 (en) * 2001-04-27 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of tumor necrosis factor receptor 2 expression
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
JP2005517433A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＮＦおよびＴＮＦレセプタースーパーファミリー遺伝子発現のＲＮＡ干渉媒介性阻害
WO2007058894A2 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
CA2666981A1 (en) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease

Also Published As

Publication number Publication date
EP2147103A2 (en) 2010-01-27
KR20180082646A (ko) 2018-07-18
KR101738655B1 (ko) 2017-05-22
KR20170056032A (ko) 2017-05-22
KR20150036814A (ko) 2015-04-07
CN104278033A (zh) 2015-01-14
AU2014203220A1 (en) 2014-07-10
CA2684724A1 (en) 2008-11-06
CA3165250A1 (en) 2008-11-06
CA2991580A1 (en) 2008-11-06
JP2014050400A (ja) 2014-03-20
WO2008131807A2 (en) 2008-11-06
AU2021204434A1 (en) 2021-07-29
CN101889086A (zh) 2010-11-17
EP2147103B1 (en) 2018-12-12
MX346434B (es) 2017-03-21
CN101889086B (zh) 2014-07-02
KR20100101050A (ko) 2010-09-16
CA3072221A1 (en) 2008-11-06
KR20150139979A (ko) 2015-12-14
US20120142759A1 (en) 2012-06-07
AU2007352163A1 (en) 2008-11-06
AU2018200382A1 (en) 2018-02-08
AU2016203220A1 (en) 2016-06-09
HK1205184A1 (en) 2015-12-11
MX2009011856A (es) 2010-06-23
WO2008131807A3 (en) 2009-02-12
AU2019208249A1 (en) 2019-08-15
JP2010524476A (ja) 2010-07-22
KR101531934B1 (ko) 2015-06-29

Similar Documents

Publication Publication Date Title
HK1205184A1 (en) Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease tnf
IL192130A0 (en) METHODS OF TRETING PAIN AND INFLAMMATION IN NEURONAL TISSUE USING IL-31Ra AND OSMRb ANTAGONISTS
IL200572A0 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
AU2007309650A8 (en) Soluble TNF receptors and their use in treatment of disease
EP2364128A4 (en) SYSTEM FOR USE IN THE TREATMENT OF SPINE FRACTURES
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
EP2276467A4 (en) ALPHA AND BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION
HK1146055A1 (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
IL198969A0 (en) Modulators of c3a receptor and methods of use thereof
HK1209053A1 (zh) 地來西坦在慢性疼痛的治療中的用途
IL206020A0 (en) Adiponectin receptor fragments and methods of use
EP2194065A4 (en) CRYSTALLINE STRUCTURE OF THE EXTRACELLULAR REGION CD147 AND USE THEREOF
IL207965A0 (en) N-substitutedbenzenepropanamide ofr denzenepropenamide derivatives for use in the treatment of pain and inflammation
IL201886A0 (en) Thromboxane receptor antagonist formulations for use in treating and preventing thrombosis
GB0724238D0 (en) Apparatus for use in the care of animals
EP1874310A4 (en) OPIOID RECEPTOR AGONIST COMPOUNDS AND THEIR USE IN PAIN TREATMENT
GB0908868D0 (en) Depsipeptide and their therapeutic use
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
GB2460181B (en) Depsipeptides and their therapeutic use
EP2175791A4 (en) BONE SCREW UNIT AND RELEVANT APPLICATION METHOD
IL193296A0 (en) Truncated il-17ra soluble receptor and methods of using in inflammation
GB2460180B (en) Depsipeptides and their therapeutic use
EP2201953A4 (en) USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER
HU3177U (en) Electro-optical device for screening of skin diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231025